Secondary outcomes of the trial at 60 month follow-up.
| Outcome | APM (n=68) | Placebo surgery (n=74) | Risk difference with 95% CI* |
| Treatment group unblinding | 8 (12) | 8 (11) | 0.01 (−0.09 to 0.12) |
| Reoperations | 7 (10) | 8 (11) | 0.00 (−0.11 to 0.10) |
| Arthroscopy | 4 (6) | 7 (9) | Not applicable |
| HTO/TKR | 3 (4) | 1 (1) | Not applicable |
| Satisfied patients | 53 (78) | 61 (84) | −0.06 (−0.19 to 0.08) |
| Improved patients | 55 (81) | 64 (88) | −0.07 (−0.19 to 0.05) |
| Returned to normal activities | 53 (78) | 54 (76) | −0.02 (−0.16 to 0.12) |
| Serious adverse events† | 0 | 0 | |
| Mechanical symptoms | 20 (29) | 9 (12) | 0.18 (0.05 to 0.31) |
| Clinical OA according to ACR criteria | 5 (8) | 6 (9) | −0.01 (−0.09 to 0.08) |
Missing data: Treatment-group unblindings: 0; Reoperations: 0; Satisfied: 5; Improved: 5; Returned to normal activities: 7; Mechanical symptoms: 4; Clinical OA: 9.
Descriptive values are numbers (percentage).
*Estimates derived from an adjusted logistic regression model using the method of standardisation to derive risk differences.
†There were no serious adverse events attributable to index surgeries between 24 and 60 months of follow-up. The only serious adverse event encountered was a knee infection after dental procedure in the APM group at 4 months after surgery.
ACR, American Colleague of Rheumatology; APM, arthroscopic partial meniscectomy; HTO, high tibial osteotomy; OA, osteoarthritis; TKR, total knee replacement.